GE Healthcare Says First Patient Scanned In A Phase 1 Trial For Fluorine-18 (18F) CD8-Targeted Imaging Radiopharmaceutical; 18F Could Allow Same-day And Subsequent Sequential Imaging, Facilitating Earlier Monitoring Once Patient Starts Treatment
Portfolio Pulse from Benzinga Newsdesk
GE Healthcare announced the first patient scanned in a Phase 1 trial for Fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical. The trial aims to study the safety and tolerability of the 18F-labeled radiopharmaceutical in patients with solid tumor malignancies, potentially allowing same-day and subsequent sequential imaging.
June 15, 2023 | 7:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GE Healthcare's Phase 1 trial for 18F CD8-targeted imaging radiopharmaceutical could potentially enable same-day and sequential imaging for patients with solid tumor malignancies.
The initiation of the Phase 1 trial for 18F CD8-targeted imaging radiopharmaceutical by GE Healthcare is a positive development for the company. If successful, it could potentially enable same-day and sequential imaging for patients with solid tumor malignancies, improving patient care and potentially increasing demand for GE Healthcare's products and services.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100